Radotinib from Cayman Chemical

A selective second generation Bcr-Abl tyrosine kinase inhibitor (IC50 = 30.6 nM); targets PDGFRα and β (IC50s = 75.5 and 130 nM, respectively); reduces viability and promotes differentiation in human acute myeloid leukemia cells